{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:50:25Z","timestamp":1777420225295,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective analysis to evaluate the real-world incidence and severity of AA-induced hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Electronic health records were used to collect baseline characteristics and prostate cancer history. Patient data, including blood pressure at each 4 (\u00b12)-week interval, were collected for 24 weeks after the initiation of AA therapy. The primary endpoint was the incidence and severity of AA-induced hypertension. The secondary endpoints include effect of different prednisone dosing regimens and prostate cancer types on hypertensive incidence and the impact of clinical pharmacists\u2019 involvement in managing AA-induced hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 142 patients who met our inclusion criteria received AA for metastatic prostate cancer, 73 (51.4%) with metastatic castration-resistant prostate cancer (mCRPC), and 69 (48.6%) with metastatic castration-sensitive prostate cancer (mCSPC). Of all, 43.7% experienced all-grade hypertension, and 28.2% experienced grade 3-4 hypertension. There was no difference in incidence of hypertension between patients receiving 5 mg of prednisone daily and those receiving 5 mg of prednisone twice daily. All-grade hypertension occurred in 39.7% of mCRPC and 47.8% of mCSPC patients ( P = 0.33). Thirty-two percent of patients were actively managed by a clinical pharmacist and had an overall trend of reduced hypertension severity after 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance:<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study found that real-world metastatic prostate cancer patients who received AA had substantially higher incidence and severity of hypertension compared with clinical trials regardless of prednisone dose. In patients with mCRPC and mCSPC, the role of prednisone dose in hypertension incidence and severity warrants further investigation. Overall, results indicate the need for closely monitoring hypertension and optimization of anti-hypertensive therapy by multidisciplinary teams in metastatic prostate cancer patients receiving AA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231223213","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:08:36Z","timestamp":1707718116000},"page":"994-1002","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-7416","authenticated-orcid":false,"given":"Brian","family":"Lam","sequence":"first","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo E.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benyam","family":"Muluneh","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA"},{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrian","family":"Proco","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young E.","family":"Whang","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"},{"name":"Division of Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine P.","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA"},{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"},{"name":"Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"bibr1-10600280231223213","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"bibr2-10600280231223213","unstructured":"Schaeffer E, Srinivas S, An Y, et al. NCCN clinical practice guidelines in oncology: prostate cancer (Version 4. 2022). Date unknown. Accessed August 7, 2022. NCCN.org"},{"key":"bibr3-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1296"},{"key":"bibr4-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"bibr5-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"bibr6-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"bibr7-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"bibr8-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0167"},{"key":"bibr9-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-020-00873-3"},{"key":"bibr10-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.11.005"},{"key":"bibr11-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1011"},{"key":"bibr12-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-019-0116-x"},{"key":"bibr13-10600280231223213","unstructured":"US Food & Drug Administration. Zytiga (abiraterone acetate) [package insert]. Date unknown. Accessed March 24, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202379s025lbl.pdf"},{"key":"bibr14-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.03.003"},{"key":"bibr15-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"bibr16-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-018-0358-3"},{"key":"bibr17-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"bibr18-10600280231223213","unstructured":"National Institutes of Health. Common terminology criteria for adverse events (CTCAE) version 5.0. Published 2017. Accessed February 10, 2022. http:\/\/ctep.cancer.gov"},{"key":"bibr19-10600280231223213","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100986"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231223213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231223213","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231223213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:34Z","timestamp":1777374814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231223213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10600280231223213"],"URL":"https:\/\/doi.org\/10.1177\/10600280231223213","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}